An injectable hydrogel platform for sustained release of eCD4-Ig

用于持续释放 eCD4-Ig 的可注射水凝胶平台

基本信息

  • 批准号:
    10841186
  • 负责人:
  • 金额:
    $ 83.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Combined anti-retroviral therapy (cART) and pre-exposure prophylaxis (PrEP) represent major milestones in the effort to eliminate AIDS and prevent new HIV-1 infections. They nonetheless have limitations. For example, a life-time use of two or three compounds delivered to most every cell and tissue in the body will likely come with undesirable, difficult-to-anticipate side effects. Access and compliance also remain concerns, especially among infected persons who have not yet been reached by our healthcare infrastructures. Similarly, PrEP requires both access and a conscious effort before a potential transmission event, something that is not always realistic for the hardest-to-reach demographics here and abroad. Here we will develop an approach that provides robust prophylaxis and perhaps effective viral suppression for six months or more after a single injection. Specifically we will optimize eCD4-Ig, a very broad and potent antibody-like molecule, for its delivery in an injectable hydrogel, and we will optimize this hydrogel for delivery of eCD4-Ig. eCD4-Ig provides highly effective protection in rhesus macaques from high-dose challenges with both SHIV-AD8 and SIVmac239. It also has the breadth and potency to suppress an established SHIV-AD8 infection. This breadth appears sufficient to suppress the wide diversity of viruses in an individual and in a population. As importantly, HIV-1 has not developed easily accessible pathways of escape from eCD4-Ig as it has from neutralizing antibodies. It is therefore an ideal payload for a safe, effective, and sustained hydrogel delivery system. As we show, these hydrogels are well-tolerated, non-immunogenic, easily manufactured, and deliverable with a high-gauge need. Importantly, they and their payloads can be immediately withdrawn in case of an adverse event. Modeling suggest that they can sustain eCD4-Ig concentrations that could provide effective prophylaxis for well over six months. We will test this possibility in human FcRn- transgenic mice and in rhesus macaques, and confirm that our best eCD4-Ig/hydrogel formulations could replace PrEP and/or cART.
项目总结 联合抗逆转录病毒疗法(CART)和暴露前预防(PrEP)是主要的 在努力消除艾滋病和预防新的艾滋病毒-1感染方面具有里程碑意义。尽管如此,他们还是有 限制。例如,两到三种化合物的终身使用几乎传递到每个细胞,并且 体内的组织可能会带来令人不快的、难以预料的副作用。访问和 遵守情况也仍然令人关切,特别是在尚未接触到的感染者中。 通过我们的医疗保健基础设施。同样,PrEP既需要访问权限,也需要有意识的努力才能 潜在的传播事件,对于最难到达的人来说并不总是现实的事情 国内外的人口统计数据。在这里,我们将开发一种方法,提供强有力的预防和 可能在一次注射后有效地抑制病毒六个月或更长时间。具体来说,我们将 优化eCD4-Ig,一种非常广泛和有效的类似抗体的分子,使其以注射形式递送 水凝胶,我们将对这种水凝胶进行优化,使其能够输送eCD4-Ig。ECD4-Ig提供高效免疫球蛋白 用SIV-AD8和SIVmac239保护恒河猴免受高剂量攻击。它还 具有抑制已建立的SHV-AD8感染的广度和效力。此宽度显示为 足以抑制病毒在个体和群体中的广泛多样性。同样重要的是, HIV-1没有像它从中和中和一样容易地从eCD4-Ig中逃脱 抗体。因此,它是安全、有效和持续的水凝胶输送系统的理想有效载荷。 正如我们所展示的,这些水凝胶具有良好的耐受性、非免疫原性、易于制造和 具有高规格需求的可交付产品。重要的是,它们和它们的有效载荷可以立即撤回 以防发生不良事件。模拟表明,它们可以维持eCD4-Ig的浓度, 提供超过六个月的有效预防措施。我们将在人类FcRN中测试这种可能性- 转基因小鼠和恒河猴,并证实我们最好的eCD4-Ig/水凝胶配方可以 更换PrEP和/或购物车。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient.
由两亲性共聚物赋形剂实现的稳定的高浓度单克隆抗体制剂。
  • DOI:
    10.1002/adtp.202200102
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Klich,JohnH;Kasse,CatherineM;Mann,JosephL;Huang,Yaoqi;d'Aquino,AndreaI;Grosskopf,AbigailK;Baillet,Julie;Fuller,GeraldG;Appel,EricA
  • 通讯作者:
    Appel,EricA
Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot.
  • DOI:
    10.1039/d2bm00819j
  • 发表时间:
    2023-03-14
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Kasse, Catherine M.;Yu, Anthony C.;Powell, Abigail E.;Roth, Gillie A.;Liong, Celine S.;Jons, Carolyn K.;Buahin, Awua;Maikawa, Caitlin L.;Zhou, Xueting;Youssef, Sawsan;Glanville, Jacob E.;Appel, Eric A.
  • 通讯作者:
    Appel, Eric A.
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates.
重链 CDR3 工程 B 细胞有助于对 HIV-1 候选疫苗进行体内评估。
  • DOI:
    10.1016/j.immuni.2023.07.003
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    32.4
  • 作者:
    He,Wenhui;Ou,Tianling;Skamangas,Nickolas;Bailey,CharlesC;Bronkema,Naomi;Guo,Yan;Yin,Yiming;Kobzarenko,Valerie;Zhang,Xia;Pan,Andi;Liu,Xin;Xu,Jinge;Zhang,Lizhou;Allwardt,AvaE;Mitra,Debasis;Quinlan,Brian;Sanders,RogierW;C
  • 通讯作者:
    C
Translational Applications of Hydrogels.
  • DOI:
    10.1021/acs.chemrev.0c01177
  • 发表时间:
    2021-09-22
  • 期刊:
  • 影响因子:
    62.1
  • 作者:
    Correa S;Grosskopf AK;Lopez Hernandez H;Chan D;Yu AC;Stapleton LM;Appel EA
  • 通讯作者:
    Appel EA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric Andrew Appel其他文献

Eric Andrew Appel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric Andrew Appel', 18)}}的其他基金

Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
用于治疗糖尿病的胰淀素类似物与胰岛素类似物的复合制剂
  • 批准号:
    10631619
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
An injectable hydrogel platform for sustained release of eCD4-Ig
用于持续释放 eCD4-Ig 的可注射水凝胶平台
  • 批准号:
    10079645
  • 财政年份:
    2020
  • 资助金额:
    $ 83.73万
  • 项目类别:
An injectable hydrogel platform for sustained release of eCD4-Ig
用于持续释放 eCD4-Ig 的可注射水凝胶平台
  • 批准号:
    10591755
  • 财政年份:
    2020
  • 资助金额:
    $ 83.73万
  • 项目类别:
An injectable hydrogel platform for sustained release of eCD4-Ig
用于持续释放 eCD4-Ig 的可注射水凝胶平台
  • 批准号:
    10170267
  • 财政年份:
    2020
  • 资助金额:
    $ 83.73万
  • 项目类别:
An injectable hydrogel platform for sustained release of eCD4-Ig
用于持续释放 eCD4-Ig 的可注射水凝胶平台
  • 批准号:
    10401854
  • 财政年份:
    2020
  • 资助金额:
    $ 83.73万
  • 项目类别:
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
用于治疗糖尿病的胰淀素类似物与胰岛素类似物的复合制剂
  • 批准号:
    10539311
  • 财政年份:
    2019
  • 资助金额:
    $ 83.73万
  • 项目类别:
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
用于治疗糖尿病的胰淀素类似物与胰岛素类似物的复合制剂
  • 批准号:
    10713360
  • 财政年份:
    2019
  • 资助金额:
    $ 83.73万
  • 项目类别:
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
用于治疗糖尿病的胰淀素类似物与胰岛素类似物的复合制剂
  • 批准号:
    10078605
  • 财政年份:
    2019
  • 资助金额:
    $ 83.73万
  • 项目类别:
Co-Formulations of Amylin Analogues with Insulin Analogues for Treatment of Diabetes
用于治疗糖尿病的胰淀素类似物与胰岛素类似物的复合制剂
  • 批准号:
    10355438
  • 财政年份:
    2019
  • 资助金额:
    $ 83.73万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 83.73万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 83.73万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 83.73万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 83.73万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 83.73万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 83.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了